US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
ドイツ
TG
Inventiva (6IV) 銘柄情報

Inventiva (6IV)

2.975

-0.13

(-4.19%)

終了 6月26日 5:00AM

Inventiva (6IV) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

2.975

( -4.19% )

買値

2.945

売値

3.00

出来高

2,855

2.96 日の範囲 3.02

2.595 52 週間の範囲 6.16

時価総額

前日終値

3.105

始値

3.00

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

355,714 €

発行済株式数

207,707,475

配当利回り

PER

-1.67

1 株当たり利益 (EPS)

-1.9

歳入

6.76M

純利益

-354.14M

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome prolifer... Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

inventivapharma.com

本社

Daix, France

設立

2026

Inventiva is listed in the Healthcare sector of the Tradegate (DE) with ticker 6IV. The last closing price for Inventiva was 3.11 €. Over the last year, Inventiva shares have traded in a share price range of 2.595 € to 6.16 €.

Inventiva currently has 207,707,475 shares in issue. The market capitalisation of Inventiva is 617.93 € million. Inventiva has a price to earnings ratio (PE ratio) of -1.67.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.155	-4.95207667732	3.13	3.19	2.96	2146	3.08480568	DE
4	-1.5399999	-34.1085256724	4.5149999	4.615	2.96	2711	3.4566509	DE
12	-1.495	-33.4451901566	4.47	5.05	2.96	1688	3.90449043	DE
26	-0.815	-21.5039577836	3.79	6.16	2.96	2264	4.71557299	DE
52	0.305	11.4232209738	2.67	6.16	2.595	3065	4.14125716	DE
156	-0.29	-8.88208269525	3.265	6.16	1.452	1947	3.68960654	DE
260	-0.29	-8.88208269525	3.265	6.16	1.452	1947	3.68960654	DE

6IV - Frequently Asked Questions (FAQ)

What is the current Inventiva share price?

The current share price of Inventiva is 2.975 €

How many Inventiva shares are in issue?

Inventiva has 207,707,475 shares in issue

What is the market cap of Inventiva?

The market capitalisation of Inventiva is EUR 617.93M

What is the 1 year trading range for Inventiva share price?

Inventiva has traded in the range of 2.595 € to 6.16 € during the past year

What is the PE ratio of Inventiva?

The price to earnings ratio of Inventiva is -1.67

What is the cash to sales ratio of Inventiva?

The cash to sales ratio of Inventiva is 97.54

What is the registered address of Inventiva?

The registered address for Inventiva is 50 rue de Dijon, Daix, Burgundy, 21121

What is the Inventiva website address?

The website address for Inventiva is inventivapharma.com

Which industry sector does Inventiva operate in?

Inventiva operates in the Biotechnology & Life Sciences sector

misterfishman

misterfishman 4分前

Buy in the mid to low trips if you must buy this peeps buy low sell high.

JD400

The Gold Reset Is Closer Than You Think Ft. Craig Hemke - LFTV Ep 278

Jun 22, 2026
In this week’s Live from the Vault, Andrew Maguire is joined by Craig Hemke to discuss why the gold and silver correction is now over, with record central bank buying and the largest Shanghai p

mikeo56

mikeo56 7分前

Up 10 % in Aussie land.
Low Volume.

ohsaycanyousee82

ohsaycanyousee82 7分前

What makes you think I’m mad?

I just read your previous post a short time ago where you state:

“This pig is done. Blarcamesine isn’t safe and isn’t efficacious. The CHMP report is a devastating indictment of Missling, his motley crew, and the board of directors. You can

vein

Dam, that’s a job title !!

Saltwaterstocks

Saltwaterstocks 10分前

https://x.com/atwectech/status/2070304306063163705?s=46

aljafy

aljafy 10分前

The only thing we can do is wait for BeBuzz to go belly-up & the ticker goes back into the R/M pool. Although the OTC R/M game is pretty dead right now

berta

Thanks NEWBIE. ANYTHING else u need to profess before I put it u on Iggy

TenKay

TenKay 12分前

“Its got the POTENTIAL to put pressure on the share price, with the
question being, how many will choose to hold on, hoping for more“

Well an LLC holding Gigafund interests (which would be Musk pre-IPO buddies) just sold $440 million worth of share equivalents for $105 a share.

1kgwxman

1kgwxman 12分前

Oh well...don't like AMFN...don't like risk...don't invest.
Smart investors have done their own research and do not rely on anonymous sources.

I'll do whatever I want with my gambling funds.
My retirement and life savings are not at risk.
I'm NOT selling, no matte

zakattack

zakattack 15分前

ron_66271

ron_66271 17分前

Gemini Claims are Unsupported. No Link Provided.

The current version doesn’t make sense.
If PAC status times-out as a legal entity on September 13, then how can PAC make distributions to us after that date?

Can Gemini support the claim of the March 21 Bar

surfkast

surfkast 17分前

Sadly, I believe George is still screwing investors from the grave. His shells are a disaster. So sad as many had faith. But his OTC history since he started the shell games is basically a scammer like all the rest. Now this one probably has major issues also.

TightCoil

TightCoil 19分前

Easy to Understand, possible reasons include,
1. A good number of foreigners working at SEC
2. Unparalleled, and Massive Staff Incompetence
3. Good Bit of Self-Dealing insider Activity
4. KIckbacks to Look The Other Way

ListenToTheTrees

ListenToTheTrees 20分前

One thing I think gets overlooked in emerging markets is that the biggest opportunities rarely announce themselves clearly in the beginning. They usually look early, messy, incomplete, and misunderstood. They often come with shifting strategies, regulatory questions, fragmented technology, evolving

Waynewayne

Waynewayne 21分前

When this thing happens and it’s going to there’s gonna be some sad puppy’s on here I can’t wait!

wronginvestor

wronginvestor 22分前

Having worked at a bank they normally hand this kind of thing over to a third party who will decide if there is anything to go after.

Once the appeal fails Hiru will effectively be dead. They will have an $6 million liability accruing interest. They will no longer be debt free and t

mick

UPTICK AT CLOSE

tdbowieknife

tdbowieknife 23分前

Yes... Everything about American Fusion points directly to an insider enrichment scam selling worthless stock to the gullible.

.

.

Watch your wallet

Buyer Beware
Social Media Promoted Frontload Pump a

ORCA

THAT OLD POS.WAS CALLING ME NAMES,AND I DID NOT KNOW WHAT I WAS TALKING ABOUT,AND AGAIN I SEND HIM THE SELLS
WHAT A STUPID IDIOT.UNREAL.I HAD TO SHOW HIM SEVERAL TIMES TO GET IT
THESE ARE SELLS THAT ALREADY HAPPENED,YOU F$CKING IDIOT.READ YOU STUPID F$CK.BUYS AND SELLS.
https://

Steady_T

Steady_T 25分前

If the speculation points toward the MAA still not satisfying MHRA after 2.5 years, it is called reality.
Obvious.

If the speculation points toward approval being imminent, it is called reasonable analysis.
Reasonable maybe.

If there were clear failure is

Aquahoya

Aquahoya 27分前

Pittsburgh Boy

Pittsburgh Boy 28分前

Keep bringing it down cause I'm looking to buy more, thank you.

iron-eagle

iron-eagle 29分前

But it’s dead right?

I mean if you consider BioAmber Inc.'s LEI updating with all new values yesterday as being "dead"...

I guess that's on you.

Also the asset class changed to "Equity / International Developed" - can you enlighten us on that change? I'

Sanarco Funds (ID)

Exchange Trading Funds

Nidda Healthcare

Ocular Therapeutix

Australian Vintage

Lincoln National

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。